Processa Pharmaceuticals, Inc. (PCSA) is approaching a closely watched clinical milestone as the company prepares to deliver interim results from its Phase 2 NGC-Cap study in advanced or metastatic breast cancer.
The update, expected in the first quarter of 2026, follows the company's January 5, 2026, announcement that it had completed enrolment and dosing of the first 20 patients required for the formal interim analysis. The study evaluates NGC-Cap - a combination of PCS6422 and Capecitabine - in patients who have already undergone multiple prior cancer treatments.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.